(Q35288804)

7 August 2017

title

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors (English)

1 reference

7 August 2017

7

Kosei Hasegawa

1 reference

7 August 2017

8

Keiichi Fujiwara

1 reference

7 August 2017

10

Yasuhiro Fujiwara

1 reference

7 August 2017

14

Noriyuki Katsumata

1 reference

7 August 2017

9

Makoto Kodaira

1 reference

7 August 2017

Yasutsuna Sasaki

1

1 reference

7 August 2017

Keisuke Miwa

2

1 reference

7 August 2017

Keishi Yamashita

3

1 reference

7 August 2017

Yu Sunakawa

4

1 reference

7 August 2017

Ken Shimada

5

1 reference

7 August 2017

Hiroo Ishida

6

1 reference

7 August 2017

Masayuki Namiki

11

1 reference

7 August 2017

Minami Matsuda

12

1 reference

7 August 2017

Yutaka Takeuchi

13

1 reference

7 August 2017

publication date

9 November 2014

1 reference

Investigational New Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

33

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

332-340

1 reference

Creative Commons Attribution 4.0 International

7 August 2017

copyright license

start time

9 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10637-014-0180-8

0 references

cites work

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Antibody pharmacokinetics and pharmacodynamics

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Overexpression of folate binding protein in ovarian cancers.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Folate-binding protein is a marker for ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387250

Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0180-8

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0180-8

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0180-8

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0180-8

[Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25380636

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25380636

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-014-0180-8

1 reference

7 August 2017

1 reference

7 August 2017

1 reference